http://hdl.handle.net/10608/15411 Sat, 04 Apr 2026 10:14:26 GMT 2026-04-04T10:14:26Z http://www.ipubli.inserm.fr:80/bitstream/id/187050/ http://hdl.handle.net/10608/15411 http://hdl.handle.net/10608/15430 Séquençage de l’ADN : La fin d’un quasi-monopole Jordan, Bertrand For the last decade, the field of DNA sequencing has been dominated by a single company, Illumina, with very limited competition. However, a new method with superior performance and lower cost has recently been announced by Roche, a major pharmaceutical and diagnostics company, and promises to have a large impact, especially (but not exclusively) for medical applications. Wed, 01 Jan 2025 00:00:00 GMT http://hdl.handle.net/10608/15430 2025-01-01T00:00:00Z http://hdl.handle.net/10608/15429 La chimiolithotrophie, ce métabolisme fréquent trop ignoré Selosse, Marc-André Wed, 01 Jan 2025 00:00:00 GMT http://hdl.handle.net/10608/15429 2025-01-01T00:00:00Z http://hdl.handle.net/10608/15428 Essais cliniques horspiste ? : À propos de l’ouvrage de Clément Tarantini et Léo Coutellec, Essayer pour soigner. Des formes de l’expérience éthique dans le soin Moulin, Anne-Marie Wed, 01 Jan 2025 00:00:00 GMT http://hdl.handle.net/10608/15428 2025-01-01T00:00:00Z http://hdl.handle.net/10608/15427 La santé commune : Antidote à la démesure, au dumping et au fake Negrutiu, Ioan Wed, 01 Jan 2025 00:00:00 GMT http://hdl.handle.net/10608/15427 2025-01-01T00:00:00Z